Merck, North Carolina

With Merck & Co. largely propping up supplies of the bladder cancer-fighting bacteria Bacillus Calmette-Guérin (BCG) in the U.S., ImmunityBio has received the FDA all-clear to help pick up the ...
Merck (NYSE: MRK) has opened a new 225,000-square ... as is another manufacturing facility the company is building that will focus on TICE BCG, a treatment for carcinoma in situ (CIS) of the ...
This program will provide patients in the U.S. with a critical alternative source of BCG, a standard-of-care treatment for bladder cancer. ImmunityBio said that Merck’s TICE BCG shortages have ...